Lisocabtagene maraleucel

lisocabtagene maraleucel · Juno Therapeutics, a subsidiary of Celgene

Drug timelines are a Plus or Pro feature.

6 regulatory and trial events tracked for Lisocabtagene maraleucel, covering 2022-12-29 to 2026-04-20. Get the full timeline:

Most recent: Clinical Trial Update: Nemtabrutinib and Lisocabtagene Maraleucel for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma [Phase 2]

See pricing